Evidence map›Paper›PMID 30991098›Full record

ArticleGene2019

Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.

Shruti Patil, Umesh T Sankpal, Myrna Hurtado, W Paul Bowman, Jeffrey Murray, Kathleen Borgmann, Anuja Ghorpade, Robert Sutphin, Don Eslin, Riyaz Basha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shruti PatilGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Umesh T SankpalTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Myrna HurtadoGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
W Paul BowmanTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX 76104, USA.
Jeffrey MurrayDepartment of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX 76104, USA.
Kathleen BorgmannGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Anuja GhorpadeGraduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Robert SutphinHaley Center for Cancer and Blood Disorders, Arnold Palmer Hospital for Children, Orlando, FL 32806, USA.
Don EslinHaley Center for Cancer and Blood Disorders, Arnold Palmer Hospital for Children, Orlando, FL 32806, USA. Electronic address: Don.Eslin@orlandohealth.com.
Riyaz BashaTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA; Department of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX 76104, USA. Electronic address: Riyaz.Basha@unthsc.edu.
University of North Texas · USArnold Palmer Hospital for Children · USCook Children's Medical Center · US

Funding

AIM-AHEAD Coordinating Center - All Four CoresOT2OD032581 · OD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI Paul Avillach, Bettina M. Beech · 2021 to 2026
$168.7M
Texas Minority Health, Research and Outreach (MiHERO)S21MD012472 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JAMBOOR K. VISHWANATHA · 2017 to 2026
$18.0M
LABORATORY OF DEVELOPMENTAL BIOLOGYR24HD000836 · NICHD · UNIVERSITY OF WASHINGTON · PI Ian Amos Glass · 1995 to 2026
$16.9M
Texas Center for Minority Health, Education, Research and OutreachU54MD006882 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JONES, HARLAN PIERRE, VISHWANATHA, JAMBOOR K. · 2017 to 2022
$6.0M
Pineal Regulation: Control of arylalkylamine N-acetyltransferaseZ01HD008836 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI KLEIN, DAVID · 2007 to 2008
$2.0M
2/2 Pilot Project 2: Langston University-UNTHSC Partnership for Cancer Research and EducationP20CA233391 · NCI · LANGSTON UNIVERSITY · PI HUNTER, TERESSA · 2018 to 2021
$777k
Intramural NIH HHS Z01 HD008836NCI NIH HHS P20 CA233391NICHD NIH HHS R24 HD000836NIH HHS OT2 OD032581NIMHD NIH HHS S21 MD012472NIMHD NIH HHS U54 MD006882
6 · The paper itself

Abstract

Medulloblastoma (MB) is characterized by highly invasive embryonal neuro-epithelial tumors that metastasize via cerebrospinal fluid. MB is difficult to treat and the chemotherapy is associated with significant toxicities and potential long-term disabilities. Previously, we showed that small molecule, clotam (tolfenamic acid: TA) inhibited MB cell proliferation and tumor growth in mice by targeting, survivin. Overexpression of survivin is associated with aggressiveness and poor prognosis in several cancers, including MB. The aim of this study was to test combination treatment involving Vincristine® (VCR), a standard chemotherapeutic drug for MB and TA against MB cells. DAOY and D283 MB cells were treated with 10 μg/mL TA or VCR (DAOY: 2 ng/mL; D283: 1 ng/mL) or combination (TA + VCR). These optimized doses were lower than individual IC

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCell CycleCell Line, TumorCell ProliferationCell SurvivalCerebellar NeoplasmsDose-Response Relationship, DrugDown-RegulationDrug SynergismGene Expression Regulation, NeoplasticHumansInhibitory Concentration 50Medulloblastomaortho-AminobenzoatesSurvivinVincristineBIRC5 protein, humanortho-AminobenzoatesSurvivintolfenamic acidVincristineCombination IndexMedulloblastomaSurvivin expressionTolfenamic acidVincristine

Identifiers

PMID30991098
PMCPMC6594553
OpenAlexW2937243539

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.